UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
    
    
SCHEDULE 13D
Under the Securities Exchange Act of 1934

 
ARMO BIOSCIENCES, INC.
(Name of Issuer)
 
COMMON STOCK
(Title of Class of Securities)
 
04225U104
(CUSIP Number)
 
OrbiMed Advisors LLC
OrbiMed Capital GP IV LLC
OrbiMed Capital GP V LLC
               
601 Lexington Avenue, 54th Floor
New York, NY 10022
Telephone:  (212) 739-6400
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

 
January 30, 2018
(Date of Event Which Requires Filing of this Statement)
 
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of § 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.
 
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7(b) for other parties to whom copies are to be sent.
 
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
 
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 

 
              
         
CUSIP No. 04225U104
 
1
NAME OF REPORTING PERSON

OrbiMed Advisors LLC
 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
 
 
(a)
(b)
3
SEC USE ONLY
 
 
 
4
SOURCE OF FUNDS

N/A
 
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
 
 
6
CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware
 
NUMBER OF SHARES
BENEFICIALLY OWNED
BY EACH REPORTING
PERSON WITH
7
SOLE VOTING POWER
 
0
 
8
SHARED VOTING POWER
 
4,118,903
 
9
SOLE DISPOSITIVE POWER
 
0
 
10
SHARED DISPOSITIVE POWER
 
4,118,903
 
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

4,118,903
 
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
 
 
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 
14.07%*
 
14
TYPE OF REPORTING PERSON (See Instructions)

IA
 
 
*
This percentage is calculated based upon 29,275,698 shares of common stock outstanding of ARMO BioSciences, Inc. (the “Issuer”), as set forth in the Issuer’s Rule 424(b)(4) Prospectus filed with the Securities and Exchange Commission on January 29, 2018.
 

             
         
CUSIP No. 04225U104
 
1
NAME OF REPORTING PERSON

OrbiMed Capital GP IV LLC
 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
 
 
(a)
(b)
3
SEC USE ONLY
 
 
 
4
SOURCE OF FUNDS

N/A
 
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
 
 
6
CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware
 
NUMBER OF SHARES
BENEFICIALLY OWNED
BY EACH REPORTING
PERSON WITH
7
SOLE VOTING POWER
 
0
 
8
SHARED VOTING POWER
 
3,709,356
 
9
SOLE DISPOSITIVE POWER
 
0
 
10
SHARED DISPOSITIVE POWER
   
3,709,356
 
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
3,709,356
 
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
 
 
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 
12.67%*
 
14
TYPE OF REPORTING PERSON (See Instructions)

OO
 
 
*
This percentage is calculated based upon 29,275,698 shares of common stock outstanding of ARMO BioSciences, Inc. (the “Issuer”), as set forth in the Issuer’s Rule 424(b)(4) Prospectus filed with the Securities and Exchange Commission on January 29, 2018.
 

         
CUSIP No. 04225U104
 
1
NAME OF REPORTING PERSON

OrbiMed Capital GP V LLC
 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
 
 
(a)
(b)
3
SEC USE ONLY
 
 
 
4
SOURCE OF FUNDS

N/A
 
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
 
 
6
CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware
 
NUMBER OF SHARES
BENEFICIALLY OWNED
BY EACH REPORTING
PERSON WITH
7
SOLE VOTING POWER
                  
0
 
8
SHARED VOTING POWER
                      
409,547
 
9
SOLE DISPOSITIVE POWER
             
0
 
10
SHARED DISPOSITIVE POWER
                      
409,547
 
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
                  
409,547
 
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
            
                
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
                     
1.40%*
 
14
TYPE OF REPORTING PERSON (See Instructions)

OO
 
 
*
This percentage is calculated based upon 29,275,698 shares of common stock outstanding of ARMO BioSciences, Inc. (the “Issuer”), as set forth in the Issuer’s Rule 424(b)(4) Prospectus filed with the Securities and Exchange Commission on January 29, 2018.
 

              
Item 1.
Security and Issuer
 
This Schedule 13D (the “Statement”)  relates to the common stock, par value $0.0001 per share (the “Shares”) of ARMO BioSciences, Inc., a corporation organized under the laws of Delaware (the “Issuer”), with its principal executive offices located at 575 Chesapeake Drive, Redwood City, CA 94063.  The Shares are listed on the NASDAQ Global Market under the ticker symbol “ARMO”.  Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

On January 30, 2018, the Issuer completed its initial public offering pursuant to which the Issuer agreed to issue and sell to the participants 7,529,412 Shares (the “IPO”).  The purchase price for each Share was $17.00.  As a result of the IPO, the Issuer’s total number of outstanding Shares increased to 29,275,698.
 
Item 2.
Identity and Background
 
(a)           This Statement is being filed by OrbiMed Advisors LLC (“Advisors”), a limited liability company organized under the laws of Delaware, OrbiMed Capital GP IV LLC (“GP IV”), a limited liability company organized under the laws of Delaware and OrbiMed Capital GP V LLC (“GP V”) (collectively, the “Reporting Persons”).
 
(b) – (c), (f) Advisors, a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the sole managing member of GP IV, which is the sole general partner of OrbiMed Private Investments IV, LP (“OPI IV”), which holds Shares, as described herein. Advisors is the sole managing member of GP V, which is the sole general partner of OrbiMed Private Investments V, LP (“OPI V”), which holds Shares, as described herein. OPI IV and OPI V are collectively referred to as the “OrbiMed Funds”. Advisors has its principal offices at 601 Lexington Avenue, 54th Floor, New York, New York 10022.
 
GP IV and GP V have their principal offices at 601 Lexington Avenue, 54th Floor, New York, New York 10022.
 
The directors and executive officers of Advisors, GP IV and GP V are set forth on Schedules I, II and III attached hereto.  Schedules I, II and III set forth the following information with respect to each such person:
 
(i)            name;
 
(ii)           business address;
 
(iii)          present principal occupation or employment and the name, principal business and address of any corporation or other organization in which such employment is conducted; and
 
(iv)          citizenship.
 
(d) – (e)  During the last five years, neither the Reporting Persons nor any person named in Schedule I, II or III have been (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
 
Item 3.
Source and Amount of Funds or Other Consideration
 
On and prior to the close of February 12, 2013, Advisors and GP IV, pursuant to their authority under the limited partnership agreement of OPI IV, as more particularly referred to in Item 6 below, caused OPI IV to purchase 8,400,000 shares of Series A Preferred Stock of the Issuer.  Prior to the closing of the IPO, each share of Series A Preferred Stock was split on a 1-for-4.7093 basis. Upon closing the IPO, each share of Series A Preferred Stock converted into Shares on a 1-for-1 basis.
 
On and prior to the close of May 16, 2014, Advisors and GP IV, pursuant to their authority under the limited partnership agreement of OPI IV, as more particularly referred to in Item 6 below, caused OPI IV to purchase 2,887,171 shares of Series B Preferred Stock of the Issuer.  Prior to the closing of the IPO, each share of Series B Preferred Stock was split on a 1-for-4.7093 basis. Upon closing the IPO, each share of Series B Preferred Stock converted into Shares on a 1-for-1 basis.
 
 

 
 
On and prior to the close of February 17, 2015 Advisors and GP IV, pursuant to their authority under the limited partnership agreement of OPI IV, as more particularly referred to in Item 6 below, caused OPI IV to purchase 2,887,171 shares of Series B Preferred Stock of the Issuer.  Prior to the closing of the IPO, each share of Series B Preferred Stock split on a 1-for-4.7093 basis. Upon closing the IPO, each share of Series B Preferred Stock converted into Shares on a 1-for-1 basis.
 
On and prior to the close of November 5, 2015 Advisors and GP IV, pursuant to their authority under the limited partnership agreement of OPI IV, as more particularly referred to in Item 6 below, caused OPI IV to purchase 1,958,445 shares of Series C Preferred Stock of the Issuer.  Prior to the closing of the IPO, each share of Series C Preferred Stock split on a 1-for-4.7093 basis. Upon closing the IPO, each share of Series C Preferred Stock converted into Shares on a 1-for-1 basis.
 
On and prior to the close of August 11, 2017 Advisors and GP IV, pursuant to their authority under the limited partnership agreement of OPI IV, as more particularly referred to in Item 6 below, caused OPI IV to purchase 1,335,688 shares of Series C-1 Preferred Stock of the Issuer.  Prior to the closing of the IPO, each share of Series C-1 Preferred Stock split on a 1-for-4.7093 basis. Upon closing of the IPO, each share of Series C-1 Preferred Stock converted into Shares on a 1-for-1 basis.
 
On and prior to the close of September 3, 2014, Advisors and GP V, pursuant to their authority under the limited partnership agreement of OPI V, as more particularly referred to in Item 6 below, caused OPI V to purchase shares of Series A Convertible Preferred Stock of ACIR BioSciences, Inc. (“Acir”), an entity which was acquired by the Issuer in October 2015 (the “Acir Acquisition”).  Upon completion of the Acir Acquisition, OPI V received 1,564,766 shares of Series B-1 Preferred Stock of the Issuer in respect of its investment in Acir.  Prior to the closing of the IPO, each share of Series B-1 Preferred Stock split on a 1-for-4.7093 basis. Upon closing the IPO, each share of Series B-1 Preferred Stock converted into Shares on a 1-for-1 basis.
 
On and prior to the close of November 5, 2015 Advisors and GP V, pursuant to their authority under the limited partnership agreement of OPI V, as more particularly referred to in Item 6 below, caused OPI V to purchase 216,448 shares of Series C Preferred Stock of the Issuer.  Prior to the closing of the IPO, each share of Series C Preferred Stock split on a 1-for-4.7093 basis. Upon closing the IPO, each share of Series C Preferred Stock converted into Shares on a 1-for-1 basis.
 
On and prior to the close of August 11, 2017 Advisors and GP V, pursuant to their authority under the limited partnership agreement of OPI V, as more particularly referred to in Item 6 below, caused OPI V to purchase 147,473 shares of Series C-1 Preferred Stock of the Issuer.  Prior to the closing of the IPO, each share of Series C-1 Preferred Stock split on a 1-for-4.7093 basis. Upon closing the IPO, each share of Series C-1 Preferred Stock converted into Shares on a 1-for-1 basis.
 
The source of funds for such purchases was the working capital of OPI IV and OPI V and capital contributions made to OPI IV and OPI V.
 
As a result of the transactions described in this Item 3, the Reporting Persons may collectively be deemed to be the beneficial owners of approximately 14.07% of the outstanding Shares.  GP IV, as the general partner of OPI IV, may be deemed to be the beneficial owner of approximately 12.67% of the outstanding Shares.  Advisors, as the managing member of GP IV, may be deemed to be the beneficial owner of approximately 12.67% of the outstanding Shares.  GP V, as the general partner of OPI V, may be deemed to be the beneficial owner of approximately 1.40% of the outstanding Shares.  Advisors, as the managing member of GP V, may be deemed to be the beneficial owner of approximately 1.40% of the outstanding Shares.  None of the Reporting Persons have acquired or disposed of any additional Shares since January 30, 2018.
                    
Item 4.
Purpose of Transaction
 
The Shares initially have been acquired by the Reporting Persons for the purpose of making an investment in the Issuer and not with the intention of acquiring control of the Issuer’s business on behalf of the OrbiMed Funds.
 
 

 
The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer’s business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer’s Shares in particular, as well as other developments and other investment opportunities.  Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time.  If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of the Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions.  Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions.
 
Except as set forth in this Statement, the Reporting Persons have not formulated any plans or proposals which relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer or the disposition of securities of the Issuer, (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries, (c) a sale or transfer of a material amount of the assets of the Issuer or any of its subsidiaries, (d) any change in the present Board of Directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board, (e) any material change in the Issuer’s capitalization or dividend policy of the Issuer, (f) any other material change in the Issuer’s business or corporate structure, (g) any change in the Issuer’s charter or bylaws or other instrument corresponding thereto or other action which may impede the acquisition of control of the Issuer by any person, (h) causing a class of the Issuer’s securities to be deregistered or delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association, (i) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act or (j) any action similar to any of those enumerated above.

Item 5.
Interest in Securities of the Issuer
 
(a)-(b)          As of the date of this filing, the Reporting Persons may be deemed, for purposes of Rule 13d-3 of the Act, directly or indirectly, including by reason of their mutual affiliation, to be the beneficial owners of the Shares described in Item 6 below.  Based upon information contained in the Issuer’s prospectus, dated January 25, 2018, filed with the SEC on January 29, 2018, the Shares held by the OrbiMed Funds constitutes approximately 14.07% of the issued and outstanding Shares.  Advisors, pursuant to its authority as the sole managing member of GP IV and GP V, and the sole general partner of the OrbiMed Funds, may be deemed to indirectly beneficially own the Shares held by the OrbiMed Funds.  GP IV, pursuant to its authority as the general partner of OPI IV, may be deemed to indirectly beneficially own the Shares held by OPI IV.  GP V, pursuant to its authority as the general partner of OPI V, may be deemed to indirectly beneficially own the Shares held by OPI V.  As a result, Advisors and GP IV share the power to direct the vote and to direct the disposition of the Shares held by OPI IV, and Advisors and GP V share the power to direct the vote and to direct the disposition of the Shares held by OPI V.  Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon (“Gordon”), Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by the OrbiMed Funds.

In addition, Advisors, GP IV and GP V, pursuant to their authority under the limited partnership agreement of OPI IV and OPI V, respectively, prior to the date of this filing, caused OPI IV and OPI V to enter into the agreements referred to in Item 6 below.
 
(c)  Except as disclosed in Item 3, none of the Reporting Persons has effected any transaction during the past sixty (60) days in any Shares.   

(d)  Not applicable.

(e)  Not applicable.
 
 

 

Item 6.
Contracts, Arrangements, Understandings or Relationship with Respect to Securities of the Issuer

In addition to the relationships between the Reporting Persons described in Items 2, 3 and 5 of the Statement, GP IV is the sole general partner of OPI IV, pursuant to the terms of the limited partnership agreement of OPI IV and GP V is the sole general partner of OPI V, pursuant to the terms of the limited partnership agreement of OPI V.  Advisors is the sole managing member of GP IV, pursuant to the terms of the limited liability company agreement of GP IV and Advisors is the sole managing member of GP V, pursuant to the terms of the limited liability company agreement of GP V.  Pursuant to these agreements and relationships, Advisors and GP IV have discretionary investment management authority with respect to the assets of OPI IV, and Advisors and GP V have discretionary investment management authority with respect to the assets of OPI V.  Such authority includes the power of GP IV to vote and otherwise dispose of securities purchased by OPI IV, and the power of GP V to vote and otherwise dispose of securities purchased by OPI V.  The number of Shares attributable to OPI IV is 3,709,356.  The number of Shares attributable to OPI V is 409,547. Advisors and GP IV may each be considered to hold indirectly 3,709,356 Shares attributable to OPI IV. Advisors and GP V may each be considered to hold indirectly 409,547 Shares attributable to OPI V.

Gordon, a Member of Advisors, has been a member of the Board of Directors of the Issuer since 2013, and, accordingly, the Reporting Persons may have the ability to affect and influence control of the Issuer. From time to time, Gordon may receive additional stock options or other awards of equity-based compensation pursuant to the Issuer’s compensation arrangements for non-employee directors.  Gordon is obligated to transfer any Shares issued under any such stock options or other awards, or the economic benefit thereof, to the Reporting Persons, which will in turn ensure that such Shares or economic benefits are provided to OPI IV and OPI V, respectively.
 
Lock-Up Agreement
 
In connection with the IPO, the OrbiMed Funds entered into a lock-up agreement with the Issuer (the “Lock-Up Agreement”).  The Lock-Up Agreement provides that, subject to limited exceptions, the OrbiMed Funds will not, during the period ending 180 days after the date of the IPO (the “Lock-Up Period”), directly or indirectly (1) sell, assign, transfer, pledge, contract to sell, or otherwise dispose of, any Shares or securities convertible into or exercisable or exchangeable for Shares with respect to which the OrbiMed Funds has or acquires the power of disposition or (2) enter into any swap or other agreement that transfers, in whole or in part, the economic risk of ownership of any such Shares.
 
After the Lock-Up Period expires, the Reporting Persons’ Shares will be eligible for sale in the public market, subject to any applicable limitations under Rule 144 under the Securities Act of 1933, as amended (the “Securities Act”), and other applicable U.S. securities laws.
 
The foregoing description of the Lock-Up Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the form of Lock-Up Agreement, a copy of which is filed as Exhibit 2 and incorporated herein by reference.

Investors Rights Agreement
 
In addition, OPI IV, OPI V and certain other stockholders of the Issuer entered into an amended and restated investors’ rights agreement with the Issuer (the “Investors Rights Agreement”), dated as of August 11, 2017.  Pursuant to the Investor Rights Agreement and subject to the terms and conditions therein, the parties agreed that:

Registration Rights
 
Following the closing of the IPO, the holders of a certain number of Shares, or their transferees, will be entitled to the registration rights set forth below with respect to registration of the resale of such shares under the Securities Act pursuant to the Investors Rights Agreement.
 
 

 

Demand Registration Rights

At any time beginning on the earlier of August 11, 2021 or six months following the effectiveness of the IPO, the holders of 50% or more of the registrable securities then outstanding of the Issuer may make a written request that the Issuer register some or all of their registrable securities, subject to certain specified conditions and exceptions.   The Issuer is required to use commercially reasonable efforts to effect the registration and will pay all registration expenses, other than underwriting discounts and commissions, related to any demand registration. Such request for registration must cover securities with an aggregate offering price of at least $5,000,000.   The Issuer is not obligated to effect more than two of these registrations.

Form S-3 Registration Rights

Pursuant to the Investor Rights Agreement, at any time after the Issuer is qualified to file a registration statement on Form S-3, and subject to limitations and conditions specified in the Investors Rights Agreement, the holders of registrable securities may make a written request that the Issuer prepare and file a registration statement on Form S-3 under the Securities Act covering their shares, so long as the aggregate price to the public, net of any underwriters’ discounts and commissions, is at least $5,000,000. The Issuer is not obligated to effect more than two of these Form S-3 registrations in any 12-month period.
 
Piggyback Registration Rights
 
Pursuant to the Investors’ Rights Agreement, if the Issuer registers any of our securities either for its own account or for the account of other security holders, the holders of these Shares are entitled to include their Shares in the registration.  Subject to certain exceptions contained in the Investors’ Rights Agreement, the Issuer and the underwriters may limit the number of Shares included in any such offering under certain circumstances, but not below 25% of the total amount of securities included in such offering. 
 
Indemnification
 
The Investor Rights Agreement contains customary cross-indemnification provisions, under which the Issuer is obligated to indemnify holders of registrable securities in the event of, among other things, material misstatements or omissions in the registration statement attributable to the Issuer, and the parties to the Investor Rights Agreement are obligated to indemnify the Issuer for, among other things, material misstatements or omissions attributable to them.
 
Termination of Registration Rights
 
The registration rights under the Investor Rights Agreement terminate upon the earliest to occur of: (i) the fourth anniversary of the completion of the IPO; (ii) a liquidation event; or (iii) with respect to the registration rights of an individual holder, such earlier time after the IPO at which the holder (a) can sell all of its Shares in compliance with Rule 144(b)(1)(i) or (b) holds one percent or less of the Issuer’s outstanding common stock and all Shares held by the holder can be sold in any three-month period without registration in compliance with Rule 144.

The foregoing description of the Investor Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Investor Rights Agreement, a copy of which is filed as Exhibit 3 and incorporated herein by reference.
 
Other than as described in this Statement, to the best of the Reporting Persons’ knowledge, there are no other contracts, arrangements, understandings or relationships (legal or otherwise) among the persons named in Item 2 and between such persons and any person with respect to any securities of the Issuer.
 
 


 
Item 7.
Materials to Be Filed as Exhibits
 
Exhibit
Description
1.
Joint Filing Agreement among OrbiMed Advisors LLC and OrbiMed Capital GP IV LLC and OrbiMed Capital GP V LLC.
2.
Form of Lock-Up Agreement (incorporated by reference to Exhibit A of Exhibit 1.1 to Amendment No. 1 to the Issuer’s Registration Statement on Form S-1 (SEC 333-222371), filed with the SEC on January 16, 2018).
3.
Amended and Restated Investors’ Rights Agreement by and among the Issuer and each of the persons listed on Schedule A thereto, dated as of August 11, 2017 (incorporated by reference to Exhibit 4.2 to the Issuer’s Registration Statement on Form S-1 (SEC 333-222371), filed with the SEC on December 29, 2017).


 
 
 

 
SIGNATURE
 
After reasonable inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated:  February 8, 2018

  
OrbiMed Advisors LLC
 
 
 
 
 
By:
/s/ Jonathan T. Silverstein
 
 
 
Name:
 Jonathan T. Silverstein
 
 
 
Title:
Member of OrbiMed Advisors LLC
 
 
 
 
 
 
 
By:
/s/ Sven H. Borho
 
 
 
Name:
 Sven H. Borho
 
 
 
Title:
Member of OrbiMed Advisors LLC
 
 
 
 
 
By:
/s/ Carl L. Gordon
 
 
 
Name:
 Carl L. Gordon
 
 
 
Title:
Member of OrbiMed Advisors LLC
 
 
 
 
 
 
                                  
 
OrbiMed Capital GP IV LLC
 
 
 
 
 
 
By:
OrbiMed Advisors LLC
its Managing Member
 
 
 
 
 
By:
/s/ Jonathan T. Silverstein
 
 
 
Name:
 Jonathan T. Silverstein
 
 
 
Title:
Member of OrbiMed Advisors LLC
 
 
 
 
 
 
By:
/s/ Sven H. Borho
 
 
 
Name:
 Sven H. Borho
 
 
 
Title:
Member of OrbiMed Advisors LLC
 
 
 
 
 
 
By:
/s/ Carl L. Gordon
 
 
 
Name:
 Carl L. Gordon
 
 
 
Title:
Member of OrbiMed Advisors LLC
 
         
                            
 
OrbiMed Capital GP V LLC
 
 
 
 
 
 
By:
OrbiMed Advisors LLC
its Managing Member
 
 
 
 
 
By:
/s/ Jonathan T. Silverstein
 
 
 
Name:
 Jonathan T. Silverstein
 
 
 
Title:
Member of OrbiMed Advisors LLC
 
 
 
 
 
 
By:
/s/ Sven H. Borho
 
 
 
Name:
 Sven H. Borho
 
 
 
Title:
Member of OrbiMed Advisors LLC
 
 
 
 
 
 
By:
/s/ Carl L. Gordon
 
 
 
Name:
 Carl L. Gordon
 
 
 
Title:
Member of OrbiMed Advisors LLC
 
         


 



 
Schedule I
 
The name and present principal occupation of each of the executive officers and directors of OrbiMed Advisors LLC are set forth below.  Unless otherwise noted, each of these persons are United States citizens and have as their business address 601 Lexington Avenue, 54th Floor, New York, NY 10022.
 
 
Name
Position with Reporting
Person
 
Principal Occupation
Samuel D. Isaly
Managing Member
Managing Member
OrbiMed Advisors LLC
Carl L. Gordon
Member
Member
OrbiMed Advisors LLC
Sven H. Borho
German and Swedish Citizen
Member
Member
OrbiMed Advisors LLC
Jonathan T. Silverstein
Member
Member
OrbiMed Advisors LLC
W. Carter Neild
Member
Member
OrbiMed Advisors LLC
Geoffrey C. Hsu
Member
Member
OrbiMed Advisors LLC
Evan D.  Sotiriou
Chief Financial Officer
 
Chief Financial Officer
OrbiMed Advisors LLC







 


 
 
Schedule II
 
The business and operations of OrbiMed Capital GP IV LLC are managed by the executive officers and directors of its managing member, OrbiMed Advisors LLC, set forth on Schedule I attached hereto.













Schedule III
 
The business and operations of OrbiMed Capital GP V LLC are managed by the executive officers and directors of its managing member, OrbiMed Advisors LLC, set forth on Schedule I attached hereto.








 

 

 

 

 
EXHIBIT INDEX
 
 
Exhibit
Description
1.
Joint Filing Agreement among OrbiMed Advisors LLC and OrbiMed Capital GP IV LLC and OrbiMed Capital GP V LLC.
2.
Form of Lock-Up Agreement (incorporated by reference to Exhibit A of Exhibit 1.1 to Amendment No. 1 to the Issuer’s Registration Statement on Form S-1 (SEC 333-222371), filed with the SEC on January 16, 2018).
3.
Amended and Restated Investors’ Rights Agreement by and among the Issuer and each of the persons listed on Schedule A thereto, dated as of August 11, 2017 (incorporated by reference to Exhibit 4.2 to the Issuer’s Registration Statement on Form S-1 (SEC 333-222371), filed with the SEC on December 29, 2017).
 
 
 
 
 
 
 
 
 
 
 

 
EXHIBIT 1

JOINT FILING AGREEMENT
 
The undersigned hereby agree that the Statement on this Schedule 13D, dated February 8, 2018 (the “Schedule 13D”), with respect to the Shares of ARMO BioSciences, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13D.  Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13D, and for the completeness and accuracy of the information concerning itself contained therein.  This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
 
IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the 8th day of February, 2018.
 
  
OrbiMed Advisors LLC
 
 
 
 
 
By:
/s/ Jonathan T. Silverstein
 
 
 
Name:
 Jonathan T. Silverstein
 
 
 
Title:
Member of OrbiMed Advisors LLC
 
 
 
 
 
 
 
By:
/s/ Sven H. Borho
 
 
 
Name:
 Sven H. Borho
 
 
 
Title:
Member of OrbiMed Advisors LLC
 
 
 
 
 
By:
/s/ Carl L. Gordon
 
 
 
Name:
 Carl L. Gordon
 
 
 
Title:
Member of OrbiMed Advisors LLC
 
 
 
 
 
 

 
OrbiMed Capital GP IV LLC
 
 
 
 
 
 
By:
OrbiMed Advisors LLC
its Managing Member
 
 
 
 
 
By:
/s/ Jonathan T. Silverstein
 
 
 
Name:
 Jonathan T. Silverstein
 
 
 
Title:
Member of OrbiMed Advisors LLC
 
 
 
 
 
 
By:
/s/ Sven H. Borho
 
 
 
Name:
 Sven H. Borho
 
 
 
Title:
Member of OrbiMed Advisors LLC
 
 
 
 
 
 
By:
/s/ Carl L. Gordon
 
 
 
Name:
 Carl L. Gordon
 
 
 
Title:
Member of OrbiMed Advisors LLC
 
         

 
OrbiMed Capital GP V LLC
 
 
 
 
 
 
By:
OrbiMed Advisors LLC
its Managing Member
 
 
 
 
 
By:
/s/ Jonathan T. Silverstein
 
 
 
Name:
 Jonathan T. Silverstein
 
 
 
Title:
Member of OrbiMed Advisors LLC
 
 
 
 
 
 
By:
/s/ Sven H. Borho
 
 
 
Name:
 Sven H. Borho
 
 
 
Title:
Member of OrbiMed Advisors LLC
 
 
 
 
 
 
By:
/s/ Carl L. Gordon
 
 
 
Name:
 Carl L. Gordon
 
 
 
Title:
Member of OrbiMed Advisors LLC